Rezera, the biotech that rebranded from NodThera earlier this year, has entered the queue for an initial public offering to bolster its decade-long NLRP3 efforts.
…
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.